MedPath

Quoin Pharmaceuticals Initiates Pediatric Trial of QRX003 for Netherton Syndrome

• Quoin Pharmaceuticals has begun clinical testing of QRX003 in a pediatric patient with Netherton Syndrome in Dublin. • The company plans to expand the trial to include three additional pediatric patients in Spain. • QRX003 is currently in late-stage clinical trials, showing promising results with no treatment-related adverse events. • Quoin is expanding its clinical sites to include locations in Saudi Arabia and the United Kingdom.

Quoin Pharmaceuticals (NASDAQ: QNRX) has commenced clinical testing of QRX003 in a pediatric patient diagnosed with Netherton Syndrome (NS) at Children's Health Ireland in Dublin, under the guidance of Dr. Alan Irvine. This marks the first evaluation of QRX003 in a pediatric population, with plans to extend the study to three additional pediatric patients in Spain.
QRX003 is currently undergoing evaluation in two late-stage clinical trials. Preliminary results have indicated improvements across multiple endpoints, with no treatment-related adverse events reported to date. These findings suggest a potentially favorable safety profile for the topical lotion.

Trial Expansion and Global Reach

In addition to the existing five clinical sites in the United States, Quoin Pharmaceuticals is broadening its clinical trial network. New sites are slated to open in Saudi Arabia and two in the United Kingdom, enhancing the geographical diversity of the study and potentially accelerating patient recruitment.
According to Dr. Michael Myers, CEO of Quoin, the expansion aims to generate a broad and diverse dataset for QRX003 in Netherton Syndrome patients. The inclusion of pediatric patients and the collaboration with Professor Irvine, a leading researcher in the field, are expected to facilitate lowering the eligibility age for future trials.

About Netherton Syndrome and QRX003

Netherton Syndrome is a rare, inherited skin disorder stemming from a mutation in the SPINK5 gene. This genetic defect leads to severe skin barrier defects, recurring infections, and a predisposition to allergies, asthma, and eczema. Patients often experience severe dehydration, chronic skin inflammation, and stunted growth. Currently, there is no cure for Netherton Syndrome, nor are there any approved therapeutic treatments available.
QRX003 is a topical lotion formulated with a proprietary delivery technology containing a broad-spectrum serine protease inhibitor. Its mechanism of action is designed to mimic the function of the LEKTI protein, which is deficient in Netherton Syndrome patients. By promoting a more normalized skin-shedding process and strengthening the skin barrier, QRX003 aims to alleviate the symptoms and improve the quality of life for individuals with Netherton Syndrome.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

Quoin Pharmaceuticals' QRX003 Shows Promise in Netherton Syndrome Trial

Quoin Pharmaceuticals' QRX003 demonstrates significant symptom reduction in a Netherton Syndrome clinical trial, with an 83% improvement observed in the first subject after 12 weeks.
The open-label study showed improvements across multiple clinical endpoints, including M-IASI, WINRS, and IGA, with no reported safety concerns and high patient satisfaction.

Quoin Pharmaceuticals Expands QRX003 Clinical Program for Netherton Syndrome and Peeling Skin Syndrome

Quoin Pharmaceuticals is assessing QRX003 in a pediatric patient with Netherton Syndrome (NS), addressing the need for early treatment in this rare genetic disease.
The company is expanding its clinical activities internationally, with new sites in Saudi Arabia and the UK, to accelerate recruitment and diversify the patient population.

Quoin Pharmaceuticals Advances QRX003 for Rare Skin Disorders, Expands Clinical Trials

Quoin Pharmaceuticals initiates an investigator-led clinical study in New Zealand to evaluate QRX003 for Peeling Skin Syndrome, a condition with no approved treatments.
The company is expanding its Netherton Syndrome clinical program internationally, opening two additional sites in the United Kingdom.

Quoin Pharmaceuticals Advances QRX003 Clinical Programs for Rare Skin Diseases

Quoin Pharmaceuticals initiates a clinical study in New Zealand for QRX003 targeting Peeling Skin Syndrome, a condition with no approved treatments.
The company expands its Netherton Syndrome clinical trials by adding two new sites in the United Kingdom, enhancing international reach.

Grunenthal's Qutenza Phase III Trial Completes Enrollment for Post-Surgical Neuropathic Pain

Grunenthal and Averitas Pharma completed enrollment for the Phase III clinical trial AV001, evaluating Qutenza in post-surgical neuropathic pain (PSNP).
The trial aims to assess the efficacy, safety, and tolerability of Qutenza (capsaicin) 8% topical system for PSNP, a condition affecting over 3 million people in the U.S. annually.

Quoin Pharmaceuticals Initiates Clinical Testing of QRX003 in Pediatric Netherton Syndrome Patient

Quoin Pharmaceuticals has begun clinical testing of QRX003 in a young child with Netherton Syndrome at Children’s Health Ireland in Dublin.
This assessment marks the first evaluation of QRX003 in a pediatric patient, with plans to expand the study to include additional pediatric subjects in Spain.

Quoin Pharmaceuticals Initiates Clinical Testing of QRX003 in Pediatric Netherton Syndrome Patient

Quoin Pharmaceuticals has begun clinical testing of QRX003 in a young child with Netherton Syndrome at Children's Health Ireland, marking the first evaluation in a pediatric patient.
The clinical assessment is led by Dr. Alan Irvine, a leading dermatologist, aiming to broaden the data set for QRX003 and potentially lower the eligibility age for treatment.

Quoin Pharmaceuticals Initiates Clinical Testing of QRX003 in Pediatric Netherton Syndrome

Quoin Pharmaceuticals has begun clinical testing of QRX003 in a young child with Netherton Syndrome, a rare genetic disease with no approved treatments.
The clinical assessment is led by Dr. Alan Irvine, a leading dermatology researcher, aiming to broaden QRX003's data set in younger patients.

Quoin Pharmaceuticals Initiates Clinical Testing of QRX003 in Pediatric Netherton Syndrome Patient

Quoin Pharmaceuticals has begun clinical testing of QRX003 in a young child with Netherton Syndrome at Children’s Health Ireland, marking the first evaluation of the drug in a pediatric patient.
The clinical assessment is led by Dr. Alan Irvine, a leading researcher in Netherton Syndrome, aiming to broaden the data set for QRX003 and potentially lower the eligibility age for treatment.

Quoin Pharmaceuticals Expands Netherton Syndrome Clinical Trials to the UK

Quoin Pharmaceuticals expands its Netherton Syndrome (NS) clinical trials to include two new sites in the United Kingdom.
The clinical sites are Great Ormond Street Hospital and St. Thomas’ Hospital, both recognized for Netherton Syndrome treatment.

Reference News

[1]
Quoin's QRX003 Shows Promise in Pediatric Netherton Syndrome Trial Expansion - Stock Titan
stocktitan.net · Nov 5, 2024

Quoin Pharmaceuticals initiates QRX003 testing in pediatric Netherton Syndrome patient in Dublin, plans expansion to Spa...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy